Get the Stockscreener App
1.33
4.32%
-0.06
After Hours:
1.33
Tiziana Life Sciences Ltd stock is traded at $1.33, with a volume of 64,472.
It is down -4.32% in the last 24 hours and down -2.92% over the past month.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
See More
Previous Close:
$1.39
Open:
$1.39
24h Volume:
64,472
Relative Volume:
0.22
Market Cap:
$169.24M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-10.23
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
+4.72%
1M Performance:
-2.92%
6M Performance:
-40.22%
1Y Performance:
+77.81%
1-Day Range:
$1.33
$1.4096
1-Week Range:
$1.27
$1.49
52-Week Range:
$0.70
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.33 | 176.87M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Investment Review: Is Tiziana Life Sciences Ltd stock overvalued or fairly priced2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Profit Review: Is Tiziana Life Sciences Ltd a stock for growth or value investors2025 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
What are the future prospects of MAIA Biotechnology IncSwing Trade & Daily Technical Forecast Reports - baoquankhu1.vn
Income Plays: What are the future prospects of Tiziana Life Sciences Ltd2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownership - Yahoo Finance
Earnings Update: Is Tiziana Life Sciences Ltd subject to activist investor interestTrade Exit Report & Precise Swing Trade Alerts - baoquankhu1.vn
Revenue Check: Is Tiziana Life Sciences Ltd subject to activist investor interestQuarterly Market Review & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Market Recap: Is KRYS stock a value trap2025 Risk Factors & Verified Momentum Stock Alerts - baoquankhu1.vn
What’s next for Tiziana Life Sciences Ltd stock2025 Buyback Activity & Safe Investment Capital Preservation Plans - mfd.ru
Can Tiziana Life Sciences Ltd expand its profit marginsWeekly Trade Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Performance Recap: Can Tiziana Life Sciences Ltd maintain its current growth rate - baoquankhu1.vn
Winners Losers: Is Omega Healthcare Investors Inc a stock for growth or value investorsWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Breakout Zone: Will Tiziana Life Sciences Ltd outperform its industry peersInsider Selling & Weekly Watchlist of Top Performers - baoquankhu1.vn
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 3.1%Should You Buy? - MarketBeat
Pullback Watch: What are the future prospects of Tiziana Life Sciences LtdJuly 2025 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
Market Recap: Does BHA have strong fundamentalsTrade Entry Summary & Short-Term High Return Ideas - baoquankhu1.vn
Tiziana's Intranasal Foralumab Study Results Published In Peer-Reviewed Journal - RTTNews
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab - The Manila Times
Tiziana Life Sciences (TLSA) Reports Positive Results in MS Stud - GuruFocus
Tiziana Life Sciences publishes positive study on intranasal MS therapy - Proactive financial news
Tiziana Life Sciences Publishes Positive Results of Intranasal Foralumab Study for Non-Active Secondary Progressive Multiple Sclerosis - Quiver Quantitative
Experimental nasal MS antibody steadies disability in small study - Stock Titan
Small cap wrap: American Resources, Tiziana Life Sciences, Digi Power X, Midnight Sun Mining... - Proactive financial news
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million - marketscreener.com
History Review: Can Tiziana Life Sciences Ltd sustain earnings growthEarnings Risk Summary & High Accuracy Trade Alerts - baoquankhu1.vn
Guidance Update: Is Tiziana Life Sciences Ltd likely to announce a buybackPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Small cap wrap: Nextech3D.ai, Aftermath Silver, Tiziana Life Sciences, AtaiBeckley… - Proactive financial news
Tiziana Life Sciences closes $8.8 million registered direct offering By Investing.com - Investing.com Nigeria
Orrick Advises Tiziana Life Sciences on Nasdaq Registered Direct Offering of Up to Approximately $17.6 Million - orrick.com
Tiziana Life Sciences Closes $8.8 Million Direct Offering of 7.04 Million Shares - Intellectia AI
Tiziana Life Sciences Raises $8.8 Million in Oversubscribed Direct Offering to Fund Phase 2 Trials - TipRanks
Tiziana Life Sciences announces closing of oversubscribed $8.8M offering - Proactive financial news
Tiziana Life Sciences closes $8.8 million registered direct offering - Investing.com
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares - The Manila Times
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares - Benzinga
Tiziana leaders invest in $8.8M raise to finish Phase 2 na-SPMS, MSA trials - Stock Titan
Volatility Watch: What is Verastem Incs P E ratio telling usJuly 2025 Setups & Safe Entry Point Alerts - baoquankhu1.vn
Tiziana Life Sciences unveils registered direct offering of up to $17.6M - Proactive financial news
Tiziana Life Sciences Raises Up to $17.6 Million in Insider-Led Direct Offering to Fund Phase 2 Trials - TipRanks
Tiziana Life Sciences Announces $8 Million Registered Direct Offering of Ordinary Shares to Support Clinical Trials - Quiver Quantitative
CEO backs $17.6M Tiziana raise to fund key na-SPMS and MSA trials - Stock Titan
Layoff Watch: How Tiziana Life Sciences Ltd stock reacts to oil pricesJuly 2025 Movers & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Aug Ideas: Is Tiziana Life Sciences Ltd stock gaining market share2025 Top Gainers & Weekly Breakout Watchlists - Bộ Nội Vụ
Tiziana Life Sciences to Showcase Intranasal Foralumab at Neuroscience Innovation Forum During JPM Week - TipRanks
US Stocks Recap: Can Columbia Sportswear Company stock sustain revenue growthJuly 2025 Technicals & Target Return Focused Stock Picks - moha.gov.vn
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco - 富途牛牛
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Tiziana Life Sciences to present at 9th Annual Neurosciences Innovation Forum - Proactive financial news
Townhall - FinancialContent
Why Tiziana Life Sciences Ltd stock is rated strong buyQuarterly Portfolio Review & Safe Swing Trade Setup Alerts - Улправда
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):